Skip to main
NTRA

Natera (NTRA) Stock Forecast & Price Target

Natera (NTRA) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 37%
Buy 53%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Natera is a leader in the fast-growing market of genetic testing, with a diverse portfolio of products that address significant medical needs. Management's focus on MRD monitoring is supported by strong clinical data and a dominant market position, providing a solid foundation for continued growth and profitability. The company's strong track record of securing reimbursement and expanding their clinical indications bodes well for their future success and potential for further upside.

Bears say

Natera is facing intense competition in the MRD and NIPT markets, with multiple well-funded players vying for market share in these key areas. While Natera may have a strong moat with its ultra-sensitive testing technology, there is a risk that competitors could replicate or innovate similar products, eroding Natera's competitive advantage. Additionally, there are uncertainties surrounding the timely realization of key catalysts, as well as potential headwinds to margin expansion from higher COGS and ASP growth.

Natera (NTRA) has been analyzed by 19 analysts, with a consensus rating of Buy. 37% of analysts recommend a Strong Buy, 53% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Natera (NTRA) Forecast

Analysts have given Natera (NTRA) a Buy based on their latest research and market trends.

According to 19 analysts, Natera (NTRA) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $334.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $334.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Natera (NTRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.